DEAF1 Rabbit Polyclonal Antibody

CAT#: TA367033

DEAF1 rabbit polyclonal antibody

Product Images

Immunohistochemistry of paraffin-embedded Human gasrtic cancer tissue using TA367033 (DEAF1 Antibody) at dilution 1/15 (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human gasrtic cancer tissue using TA367033 (DEAF1 Antibody) at dilution 1/15, treated with synthetic peptide. (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using TA367033 (DEAF1 Antibody) at dilution 1/15 (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using TA367033 (DEAF1 Antibody) at dilution 1/15, treated with synthetic peptide. (Original magnification: ×200)

Specifications

Product Data

• Applications: IHC
• Recommended Dilution: IHC: 25-100
  Positive control: Human gasrtic cancer
  Predicted cell location: Cytoplasm
• Reactivities: Human
• Host: Rabbit
• Isotype: IgG
• Clonality: Polyclonal
• Immunogen: Synthetic peptide of human DEAF1
• Formulation: pH7.4 PBS, 0.05% NaN3, 40% Glycerol
• Concentration: lot specific
• Purification: Antigen affinity purification
• Conjugation: Unconjugated
• Storage: Store at -20°C.
• Stability: 1 year
• Database Link:
  UniProt ID O75398
• Background: Suppressin, also known as DEAF1 (deformed epidermal autoregulatory factor 1), SPN, NUDR (nuclear DEAF-1-related transcriptional regulator), or ZMYND5 (zinc finger MYND domain-containing protein 5), is a transcription factor required for embryonic development. Suppressin contains one SAND domain and one C-terminal MYND-type zinc finger. It interacts with LMO4 and CLIM-2, suggesting that it plays a role mediating cell fate and embryonic pattern formation. Suppressin is expressed in a variety of tissues and localizes to the nucleus. Several isoforms exist due to alternative splicing and, depending on the isoform, Suppressin is secreted in some cell types. Secreted Suppressin can function to inhibit cell proliferation, arresting cells in the G0 or G1 phase. Mutations in the gene encoding Suppressin may result in a growth advantage leading to the development and progression of neoplasia. This suggest that Supressin is a potential target for cancer therapy.